Imidazole → (+/-)-(3R,4R)-benzyl 4-((tert-butyldimethylsilyl)oxy)-3-morpholinopiperidine-1-carboxylate

HRID 1430856ノート

反応式

HRID 1430856 の反応式
[CH:1]12[O:7][CH:6]1[CH2:5][CH2:4][N:3]([C:8]([O:10][CH2:11][C:12]1[CH:17]=[CH:16][CH:15]=[CH:14][CH:13]=1)=[O:9])[CH2:2]2.[NH:18]1[CH2:23][CH2:22][O:21][CH2:20][CH2:19]1.Cl([O-])(=O)(=O)=O.[Li+].N1C=CN=C1.[C:35]([Si:39]([CH3:42])([CH3:41])Cl)([CH3:38])([CH3:37])[CH3:36]>C(#N)C.ClCCl>[Si:39]([O:7][C@@H:6]1[CH2:5][CH2:4][N:3]([C:8]([O:10][CH2:11][C:12]2[CH:17]=[CH:16][CH:15]=[CH:14][CH:13]=2)=[O:9])[CH2:2][C@H:1]1[N:18]1[CH2:23][CH2:22][O:21][CH2:20][CH2:19]1)([C:35]([CH3:38])([CH3:37])[CH3:36])([CH3:42])[CH3:41].[Si:39]([O:7][C@H:1]1[C@H:6]([N:18]2[CH2:23][CH2:22][O:21][CH2:20][CH2:19]2)[CH2:5][CH2:4][N:3]([C:8]([O:10][CH2:11][C:12]2[CH:17]=[CH:16][CH:15]=[CH:14][CH:13]=2)=[O:9])[CH2:2]1)([C:35]([CH3:38])([CH3:37])[CH3:36])([CH3:42])[CH3:41]

参加物

9

反応物 5

HCID 795ImidazoleHCID 8083MorpholineHCID 28928tert-Butyldimethylsilyl chlorideHCID 13186888Benzyl 7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylateHCID 23665649Lithium perchlorate

生成物 2

HCID 86708547(+/-)-(3R,4R)-benzyl 4-((tert-butyldimethylsilyl)oxy)-3-morpholinopiperidine-1-carboxylateHCID 86708548(+/-)-(3R,4R)-benzyl 3-((tert-butyldimethylsilyl)oxy)-4-morpholinopiperidine-1-carboxylate

試薬・触媒・溶媒 2

HCID 6342Acetonitrile溶媒HCID 6344Dichloromethane溶媒

実験手順

A mixture of benzyl 7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylate (prepared according to a published literature procedure: Fink, Brian, et al., WO 2005/066176, 700 mg, 3.00 mmol), morpholine (0.581 mL, 6.00 mmol), and lithium perchlorate (639 mg, 6.00 mmol) in acetonitrile (10 mL) was heated at 80° C. for 4 h. Solvent was evaporated and the crude intermediate was dissolved in dichloromethane (10 mL), imidazole (654 mg, 9.60 mmol) and tert-butyldimethylchlorosilane (1357 mg, 9.00 mmol) were added. The reaction mixture was stirred at room temperature overnight The reaction was diluted with dichloromethane and washed with water and brine, dried over sodium sulfate, filtered, and concentrated. The crude product was purified by flash chromatography on silica gel using an automated ISCO system (220 g gold column, eluting with 5-30% ethyl acetate/hexanes) to give (+/−)-(3R,4R)-benzyl 4-((tert-butyldimethylsilyl)oxy)-3-morpholinopiperidine-1-carboxylate (Isomer A, 0.39 g,) as a colorless oil and (+/−)-(3R,4R)-benzyl 3-((tert-butyldimethylsilyl)oxy)-4-morpholinopiperidine-1-carboxylate (Isomer B, 0.43 g) as a colorless oil. The structures were confirmed by NMR studies (1H-1D, 13C-1D, COSY, NOESY, dept-1H-13C-HSQC, 1H-13C-HMBC).

後処理

  1. customprepared
  2. customSolvent was evaporated
  3. dissolutionthe crude intermediate was dissolved in dichloromethane (10 mL)
  4. washwashed with water and brine
  5. dry with materialdried over sodium sulfate
  6. filtrationfiltered
  7. concentrationconcentrated
  8. customThe crude product was purified by flash chromatography on silica gel using
  9. washan automated ISCO system (220 g gold column, eluting with 5-30% ethyl acetate/hexanes)

出典と根拠

ORDレコード
ord-4ed0f56cc0604b2096ad2afa4326cfa2
出典データセット
uspto-grants-2015_01
特許番号
US08940736B2

反応ノート

読み込み中…